Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease

Published:2018-02-16 Issue:3 Volume:24 Page:465-466
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Katsanos Konstantinos H¹,Papamichael Konstantinos²,Cheifetz Adam S²,Christodoulou Dimitrios K¹

Affiliation:

1. Division of Gastroenterology, University Hospital and Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece

2. Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard University, Boston, Massachusetts

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/article-pdf/24/3/465/24250588/izx092.pdf

Reference18 articles.

1. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases;Papamichael;Aliment Pharmacol Ther,2015

2. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy;Choe;Ann Rheum Dis,2017

3. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study;Yoo;Ann Rheum Dis,2013

4. Antibodies to infliximab in remicade-treated rheumatic patients show identical reactivity towards biosimilars;Ruiz-Argüello;Ann Rheum Dis,2016

5. Cross-immunogenicity: antibodies to infliximab in remicade-treated patients with IBD similarly recognise the biosimilar remsima;Ben-Horin;Gut,2016